A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

NCT03669393 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinal Telangiectasis
Idiopathic Juxtafoveal Retinal Telangiectasia

Interventions

DRUG: THR-317 8mg

Sponsor

ThromboGenics